2026-05-16T22:07:40Zhttps://repisalud.isciii.es/rest/oai/request

oai:repisalud.isciii.es:20.500.12105/173462024-09-21T22:24:32Zcom_20.500.12105_15322com_20.500.12105_2051col_20.500.12105_16927col_20.500.12105_16961

00925njm 22002777a 4500 dc Cassinello, J author Arranz, J Á author Piulats, J M author Sánchez, A author Pérez-Valderrama, B author Mellado, B author Climent, M Á author Olmos, D author Carles, J author Lázaro, M author 2017-11-13 Androgen deprivation treatment was the only treatment available for metastatic prostate cancer until recently, with docetaxel as the only treatment with a proven survival benefit in castration-resistant prostate cancer (CRPC). Several drugs have been approved in the castration-resistant disease (sipuleucel-T, cabazitaxel, abiraterone, enzalutamide, radium-223). More recently, docetaxel and abiraterone have been moved to the hormone-sensitive disease setting, achieving better patient survival. The purpose of this article is to define the state of the art in the treatment of prostate carcinoma. 10.1007/s12094-017-1783-2 1699-3055 Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico http://hdl.handle.net/10668/11795 29134562 http://hdl.handle.net/20.500.12105/17346 Abiraterone Androgen deprivation treatment Cabazitaxel Castration-resistant prostate cancer Docetaxel Enzalutamide Hormone-sensitive advanced prostate cancer Radium 223 SEOM clinical guidelines for the treatment of metastatic prostate cancer (2017).